Literature DB >> 10854900

Metabotropic glutamate autoreceptors of the mGlu(5) subtype positively modulate neuronal glutamate release in the rat forebrain in vitro.

L S Thomas1, D E Jane, J R Harris, M J Croucher.   

Abstract

In the present study we have examined the role of presynaptic group I metabotropic glutamate (mGlu) receptors in the control of neuronal glutamate release using rat forebrain slices pre-loaded with [(3)H]D-aspartate. We have also addressed the question of which group I mGlu receptor subtype, mGlu(1) or mGlu(5), mediates the facilitatory response observed by the use of a range of established and some more novel agonists and antagonists showing selectivity for these receptors. The electrically-stimulated release of pre-loaded [(3)H]D-aspartate from rat forebrain slices was markedly potentiated by the potent group I mGlu receptor agonist, L-quisqualic acid (L-QUIS), in a concentration-dependent manner (EC(50) 17.31 microM). This response was inhibited by the mGlu receptor antagonists (S)-MCPG (100 microM) and (RS)-MTPG (100 microM) but not by the AMPA-type ionotropic glutamate receptor antagonist, NBQX (100 microM). The selective group I mGlu receptor agonist (S)-3, 5-dihydroxyphenylglycine ((S)-DHPG) also enhanced electrically-stimulated efflux of label, although responses diminished with high (10-100 microM) concentrations of the agonist. Maximum responses were fully restored when (S)-DHPG (10 microM) was applied in the presence of the proposed mGlu(5) receptor desensitization inhibitor, cyclothiazide (10 microM). The positive modulatory response to (S)-DHPG (1 microM) was powerfully inhibited by (S)-MCPG (IC(50) 0.08 microM) but was resistant to the mGlu(1) receptor antagonists, (RS)-AIDA (1-500 microM), CPCCOEt (0.1-100 microM) and (+)-2-methyl-4-carboxyphenylglycine (LY367385) (0.1-10 microM). The recently developed, selective mGlu(5) receptor agonist (RS)-2-chloro-5-hydroxyphenylglycine ((RS)-CHPG) enhanced electrically-stimulated [(3)H]D-aspartate efflux from rat forebrain slices with a similar concentration-response profile to that of (S)-DHPG. Responses to this receptor subtype-selective agonist were also blocked by (S)-MCPG (IC(50) 1.13 microM) but were unaffected by (RS)-AIDA (500 microM), CPCCOEt (100 microM) or LY367385 (10 microM). These results indicate that the positive modulation of neuronal glutamate release seen in the rat forebrain in the presence of group I mGlu receptor agonists is mediated by presynaptically located mGlu(5) glutamate autoreceptors. The pharmacological profile of these receptors appears to be distinct from that of postsynaptic mGlu receptors. Novel antagonists acting at these presynaptic receptors may provide new drugs for the experimental therapy of a range of acute or chronic neurodegenerative disorders.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10854900     DOI: 10.1016/s0028-3908(99)00223-3

Source DB:  PubMed          Journal:  Neuropharmacology        ISSN: 0028-3908            Impact factor:   5.250


  15 in total

Review 1.  Neuroprotective and abstinence-promoting effects of acamprosate: elucidating the mechanism of action.

Authors:  Philippe De Witte; John Littleton; Philippe Parot; George Koob
Journal:  CNS Drugs       Date:  2005       Impact factor: 5.749

Review 2.  Monoamines in glioblastoma: complex biology with therapeutic potential.

Authors:  Seamus Patrick Caragher; Robert Raymond Hall; Riasat Ahsan; Atique U Ahmed
Journal:  Neuro Oncol       Date:  2018-07-05       Impact factor: 12.300

3.  Endogenous sulphur-containing amino acids: potent agonists at presynaptic metabotropic glutamate autoreceptors in the rat central nervous system.

Authors:  M J Croucher; L S Thomas; H Ahmadi; V Lawrence; J R Harris
Journal:  Br J Pharmacol       Date:  2001-07       Impact factor: 8.739

4.  Activation of intracellular metabotropic glutamate receptor 5 in striatal neurons leads to up-regulation of genes associated with sustained synaptic transmission including Arc/Arg3.1 protein.

Authors:  Vikas Kumar; Paul G Fahey; Yuh-Jiin I Jong; Narendrakumar Ramanan; Karen L O'Malley
Journal:  J Biol Chem       Date:  2011-12-16       Impact factor: 5.157

5.  Negative versus positive allosteric modulation of metabotropic glutamate receptors (mGluR5): indices for potential pro-cognitive drug properties based on EEG network oscillations and sleep-wake organization in rats.

Authors:  A Ahnaou; X Langlois; T Steckler; J M Bartolome-Nebreda; W H I M Drinkenburg
Journal:  Psychopharmacology (Berl)       Date:  2014-10-18       Impact factor: 4.530

6.  Modulation of aspartate release by ascorbic acid and endobain E, an endogenous Na+, K+ -ATPase inhibitor.

Authors:  M G Bersier; V Miksztowicz; C Peña; G Rodríguez de Lores Arnaiz
Journal:  Neurochem Res       Date:  2005-04       Impact factor: 3.996

7.  Activation of metabotropic glutamate 5 (mGlu5) receptors induces spontaneous excitatory synaptic currents in layer V pyramidal cells of the rat prefrontal cortex.

Authors:  Gerard J Marek; Ce Zhang
Journal:  Neurosci Lett       Date:  2008-07-04       Impact factor: 3.046

8.  Functional interactions between presynaptic NMDA receptors and metabotropic glutamate receptors co-expressed on rat and human noradrenergic terminals.

Authors:  E Luccini; V Musante; E Neri; M Brambilla Bas; P Severi; M Raiteri; A Pittaluga
Journal:  Br J Pharmacol       Date:  2007-06-25       Impact factor: 8.739

9.  Metabotropic Glutamate Receptor 5 and Glutamate Involvement in Major Depressive Disorder: A Multimodal Imaging Study.

Authors:  Chadi G Abdallah; Jonas Hannestad; Graeme F Mason; Sophie E Holmes; Nicole DellaGioia; Gerard Sanacora; Lihong Jiang; David Matuskey; Ritvij Satodiya; Fabrizio Gasparini; Xin Lin; Jonathan Javitch; Beata Planeta; Nabeel Nabulsi; Richard E Carson; Irina Esterlis
Journal:  Biol Psychiatry Cogn Neurosci Neuroimaging       Date:  2017-04-06

Review 10.  Dysregulation of group-I metabotropic glutamate (mGlu) receptor mediated signalling in disorders associated with Intellectual Disability and Autism.

Authors:  Simona D'Antoni; Michela Spatuzza; Carmela M Bonaccorso; Sebastiano A Musumeci; Lucia Ciranna; Ferdinando Nicoletti; Kimberly M Huber; Maria Vincenza Catania
Journal:  Neurosci Biobehav Rev       Date:  2014-02-15       Impact factor: 8.989

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.